Filter News
Area of Research
News Topics
- (-) Biotechnology (1)
- (-) Energy Storage (2)
- (-) Frontier (1)
- (-) Isotopes (2)
- (-) National Security (1)
- 3-D Printing/Advanced Manufacturing (5)
- Advanced Reactors (2)
- Artificial Intelligence (1)
- Big Data (1)
- Bioenergy (4)
- Biology (4)
- Biomedical (5)
- Climate Change (1)
- Composites (1)
- Computer Science (8)
- Coronavirus (5)
- Cybersecurity (2)
- Decarbonization (2)
- Environment (3)
- Fusion (2)
- High-Performance Computing (1)
- Materials (6)
- Materials Science (14)
- Microscopy (1)
- Nanotechnology (6)
- Neutron Science (40)
- Nuclear Energy (8)
- Physics (7)
- Quantum Science (5)
- Security (1)
- Space Exploration (3)
- Summit (4)
- Sustainable Energy (3)
- Transformational Challenge Reactor (1)
- Transportation (2)
Media Contacts
A team of scientists led by the Department of Energy’s Oak Ridge National Laboratory designed a molecule that disrupts the infection mechanism of the SARS-CoV-2 coronavirus and could be used to develop new treatments for COVID-19 and other viral diseases.
Paul Langan will join ORNL in the spring as associate laboratory director for the Biological and Environmental Systems Science Directorate.
Researchers at ORNL have developed a new method for producing a key component of lithium-ion batteries. The result is a more affordable battery from a faster, less wasteful process that uses less toxic material.
Researchers at ORNL and the University of Tennessee, Knoxville, discovered a key material needed for fast-charging lithium-ion batteries. The commercially relevant approach opens a potential pathway to improve charging speeds for electric vehicles.
Six ORNL scientists have been elected as fellows to the American Association for the Advancement of Science, or AAAS.
After its long journey to Mars beginning this summer, NASA’s Perseverance rover will be powered across the planet’s surface in part by plutonium produced at the Department of Energy’s Oak Ridge National Laboratory.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.